Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07361874 · ClinicalTrials.gov registry record · NA
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 75
- Enrollment target
NCT07361874 is a NA study that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 75 participants.
The verdict
NCT07361874, a NA study, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
Study Summary
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn how these treatments impact body composition, blood pressure, cholesterol, inflammation, muscle strength, and quality of life. The main questions the study aims to answer are: 1. Does adrenalectomy or semaglutide improve insulin resistance more in people with MACS? 2. How do these treatments change cortisol patterns and other cardiometabolic risk factors? 3. Do people with MACS respond differently to semaglutide compared to matched adults without MACS? Participants will: 1. Receive either adrenalectomy or semaglutide if they have MACS, or semaglutide if they are matched controls 2. Complete clinic visits and phone visits over about 26-30 weeks 3. Undergo metabolic testing such as blood tests, urine steroid profiling, body composition scans, blood pressure monitoring, muscle strength testing, and questionnaires about health and well-being
Interventions
- PROCEDURE Intervention 1: Adrenalectomy
- DRUG Intervention 2: Semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2030-05-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07361874
The ClinicalTrials.gov registry entry for NCT07361874 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intervention 1: Adrenalectomy is the first listed.
NCT07361874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07361874 about?
NCT07361874 is a clinical study titled "IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion". The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn h...
What is the current status of trial NCT07361874?
This trial is currently recruiting. It is a NA study. The enrollment target is 75 participants. The study started on 2026-03-05. Estimated completion is 2030-05-31.
What interventions are being tested in trial NCT07361874?
The interventions under investigation include: Intervention 1: Adrenalectomy (PROCEDURE), Intervention 2: Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07361874?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.